FULC - Fulcrum Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-88.65M

Cash

297.8M

Avg Qtr Burn

-24.77M

Short % of Float

7.88%

Insider Ownership

4.83%

Institutional Own.

90.44%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Losmapimod (p38 inhibitor) Details Muscle degeneration, Muscle weakness	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FTX-6058 (EED inhibitor) Details Sickle cell disease, COVID-19	Phase 1b Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Losmapimod (p38 inhibitor) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.